Payment overview · 2025
General Payments
$1,405.44
82 reported records · 18 companies
Healthcare provider profile · identity verified
Clayton H. Davis, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SYLACAUGA, AL · NPI 1205923554
Verified facts
What the public records show
CMS Open Payments records show Clayton H. Davis, M.D. received $1,405.44 in general payments during 2025 across 82 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 20.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Mounjaro, Ozempic, Rybelsus, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 181 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 322 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synjardy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 322 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Rybelsus by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $291.06 | 20.7% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $284.55 | 20.2% | 12 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $136.05 | 9.7% | 15 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $135.47 | 9.6% | 14 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $82.07 | 5.8% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $79.12 | 5.6% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $60.28 | 4.3% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $58.40 | 4.2% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $48.27 | 3.4% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $38.85 | 2.8% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $34.84 | 2.5% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $30.54 | 2.2% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.66 | 1.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.40 | 1.6% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.27 | 1.6% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $20.44 | 1.4% | 1 | 2025 |
| Rhythm Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.14 | 1.4% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $16.03 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,405.44 | 82 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $291.06 | 12 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $194.18 | 8 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $104.21 | 10 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $100.63 | 9 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $79.12 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $71.85 | 10 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $69.82 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $68.95 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $63.62 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $63.62 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $62.07 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $60.28 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $58.40 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $58.40 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $48.27 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $38.85 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $34.84 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $31.84 | 5 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $30.54 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $25.66 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $25.59 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $22.40 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $22.27 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $20.44 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| IMCIVREE Normalized: imcivree |
Drug | Rhythm Pharmaceuticals, Inc. | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $16.03 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $4.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 181 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 322 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 96 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 152 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 36 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
181 | 49 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
322 | 70 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
322 | 70 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
96 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
152 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
36 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1165 | 350 |
| Amlodipine Besylate | Amlodipine Besylate | 752 | 219 |
| Pantoprazole Sodium | Pantoprazole Sodium | 628 | 170 |
| Carvedilol | Carvedilol | 572 | 169 |
| Metformin Hcl | Metformin Hcl | 511 | 143 |
| Lisinopril | Lisinopril | 494 | 184 |
| Levothyroxine Sodium | Levothyroxine Sodium | 445 | 108 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 421 | 81 |
| Furosemide | Furosemide | 361 | 101 |
| Omeprazole | Omeprazole | 323 | 97 |
| Jardiance | Empagliflozin | 322 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 312 | 94 |
| Eliquis | Apixaban | 310 | 59 |
| Losartan Potassium | Losartan Potassium | 274 | 68 |
| Potassium Chloride | Potassium Chloride | 268 | 66 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 260 | 84 |
| Ezetimibe | Ezetimibe | 251 | 78 |
| Hydrochlorothiazide | Hydrochlorothiazide | 245 | 74 |
| Tramadol Hcl | Tramadol Hcl | 244 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 226 | 78 |
| Sertraline Hcl | Sertraline Hcl | 216 | 48 |
| Montelukast Sodium | Montelukast Sodium | 202 | 76 |
| Farxiga | Dapagliflozin Propanediol | 181 | 49 |
| Gabapentin | Gabapentin | 178 | 67 |
| Clopidogrel | Clopidogrel Bisulfate | 164 | 59 |
| Pravastatin Sodium | Pravastatin Sodium | 164 | 53 |
| Allopurinol | Allopurinol | 153 | 47 |
| Ozempic | Semaglutide | 152 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 148 | 39 |
| Famotidine | Famotidine | 137 | 47 |
| Ropinirole Hcl | Ropinirole Hcl | 137 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 135 | 41 |
| Meloxicam | Meloxicam | 130 | 54 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 128 | 37 |
| Januvia | Sitagliptin Phosphate | 123 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 122 | 49 |
| Tizanidine Hcl | Tizanidine Hcl | 122 | 47 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 121 | 31 |
| Xarelto | Rivaroxaban | 119 | 20 |
| Entresto | Sacubitril/Valsartan | 118 | 21 |
| Trazodone Hcl | Trazodone Hcl | 112 | 20 |
| Atenolol | Atenolol | 110 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 109 | 19 |
| Clonazepam | Clonazepam | 105 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 105 | 51 |
| Celecoxib | Celecoxib | 103 | 38 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 102 | 20 |
| Alprazolam | Alprazolam | 98 | 14 |
| Memantine Hcl | Memantine Hcl | 98 | 20 |
| Mounjaro | Tirzepatide | 96 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 92 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 91 | 32 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 83 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 81 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 81 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 79 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 79 | 35 |
| Donepezil Hcl | Donepezil Hcl | 75 | 28 |
| Cefdinir | Cefdinir | 73 | 66 |
| Methylprednisolone | Methylprednisolone | 73 | 63 |
| Meclizine Hcl | Meclizine Hcl | 71 | 29 |
| Pregabalin | Pregabalin | 71 | 26 |
| Azithromycin | Azithromycin | 69 | 59 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 68 | suppressed |
| Ramipril | Ramipril | 67 | 22 |
| Alendronate Sodium | Alendronate Sodium | 66 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 63 | 54 |
| Zolpidem Tartrate | Zolpidem Tartrate | 63 | 15 |
| Simvastatin | Simvastatin | 56 | 20 |
| Benazepril Hcl | Benazepril Hcl | 55 | 12 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 15 |
| Lorazepam | Lorazepam | 52 | 16 |
| Risperidone | Risperidone | 51 | suppressed |
| Chlorthalidone | Chlorthalidone | 50 | 20 |
| Trulicity | Dulaglutide | 48 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 47 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | 18 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 45 | 11 |
| Mirtazapine | Mirtazapine | 45 | 12 |
| Sucralfate | Sucralfate | 45 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 44 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 44 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 44 | 41 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 41 | suppressed |
| Myrbetriq | Mirabegron | 41 | 16 |
| Bupropion Xl | Bupropion Hcl | 40 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 39 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 26 |
| Levetiracetam | Levetiracetam | 38 | suppressed |
| Levofloxacin | Levofloxacin | 38 | 35 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 36 | suppressed |
| Fluconazole | Fluconazole | 36 | 31 |
| Trintellix | Vortioxetine Hydrobromide | 36 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 35 | 11 |
| Dutasteride | Dutasteride | 35 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 35 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Rybelsus | Semaglutide | 35 | suppressed |
| Naproxen | Naproxen | 34 | suppressed |
| Nystatin | Nystatin | 34 | 19 |
| Repatha Sureclick | Evolocumab | 34 | suppressed |
| Spironolactone | Spironolactone | 34 | 13 |
| Fenofibrate | Fenofibrate | 33 | 11 |
| Prednisone | Prednisone | 32 | 22 |
| Tresiba Flextouch U-100 | Insulin Degludec | 32 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 31 | suppressed |
| Cephalexin | Cephalexin | 30 | 19 |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 30 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 30 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | suppressed |
| Estradiol | Estradiol | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | 11 |
| Temazepam | Temazepam | 28 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 27 | suppressed |
| Ibuprofen | Ibuprofen | 26 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 25 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 25 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | 16 |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Fentanyl | Fentanyl | 19 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 18 | suppressed |
| Linezolid | Linezolid | 18 | 16 |
| Livalo | Pitavastatin Calcium | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 16 |
| Clotrimazole | Clotrimazole | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 14 |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 14 | suppressed |
| Febuxostat | Febuxostat | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Klor-Con | Potassium Chloride | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 13 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Nucynta | Tapentadol Hcl | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 11 | suppressed |
| Repatha Syringe | Evolocumab | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,405.44 · 82 records | Bayer Healthcare Pharmaceuticals Inc. | AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, EVENITY, FANAPT, FARXIGA, GEMTESA, IMCIVREE, INSPIRE, JARDIANCE, Kerendia, Korlym, MOUNJARO, NEXLETOL, OTEZLA, Ozempic, PROLIA, QULIPTA, REPATHA, REXULTI, Rybelsus, TRINTELLIX, UBRELVY, VRAYLAR, Wegovy, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error